Ticker LaunchReverse merger · Completed · VIRX
Viracta Therapeutics, Inc.
Reverse merger with Sunesis Pharmaceuticals, Inc.
Viracta Therapeutics, Inc. merged into Sunesis Pharmaceuticals, Inc., a Nasdaq-listed biopharmaceutical company, in a reverse merger that takes the private company public. The deal was announced on Nov 30, 2020 and closed on Feb 24, 2021. The combined company trades as Viracta Therapeutics, Inc. (VIRX) on Nasdaq.
Viracta Therapeutics is a clinical-stage precision oncology company developing treatments for virus-associated malignancies. Its lead program targets Epstein-Barr virus-positive relapsed or refractory lymphoma, with a registration trial planned and a broader pipeline in virus-associated cancers.
- Status
- Completed
- Private company
- Viracta Therapeutics, Inc.
- Public company
- Sunesis Pharmaceuticals, Inc.
- Public company business before
- Nasdaq-listed biopharmaceutical company
- Announced
- Nov 30, 2020
- Closed
- Feb 24, 2021
- Combined company
- Viracta Therapeutics, Inc. (VIRX)
- Exchange
- Nasdaq
- Sector
- Biotech & pharma
More on this deal for subscribers
- Ownership split between private and public holders
- Concurrent financing and investors
- Reverse stock split
- Analyst notes from the filings
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
Other completed reverse mergers
- Medical Outcomes Research Analytics, LLCinto Helix Technologies, Inc. · Mar 2, 2021
- Riley Exploration - Permian, LLCinto Tengasco, Inc. · Feb 26, 2021
- SmartKem Limitedinto Parasol Investments Corp · Feb 23, 2021
- The Home Integrator Holdings, LLC (HI Solutions)into RC-1, Inc. · Feb 22, 2021
- Alkeon Creators, Inc.into Born, Inc. · Feb 16, 2021
- Coeptis Pharmaceuticals, Inc.into Vinings Holdings, Inc. · Feb 12, 2021